It has already been reported that damaging mutations in the IFNγ signaling pathway and antigen presentation pathway are associated with metastasis and higher resistance to the checkpoint blocking therapy with anti-PD-L1/PD-1 in a number of tumor types, including bladder cancer (29, 30, 40). This evidence concerns the gene IFNG and urinary bladder carcinoma.